headquarters_2_web

Lilly €200m expansion of Cork site under review

pharmafile | February 13, 2017 | News story | Manufacturing and Production, Sales and Marketing Eli Lilly, Ireland, cork 

Eli Lilly’s planned €200m investment to its manufacturing plant in Kindsdale, County Cork, is now under-review. The expansion would bring much needed investment and employment to the area and there are concerns that it could be due to Trump’s recent overtures to the pharmaceutical industry.

The manufacturing site currently employs 500 people and the planned expansion would have a knock-on effect of creating several hundred more. Ireland has thrived on the back of being open to investment after the financial crisis.

President Trump now threatens to undermine this progress with his desire to bring manufacturing jobs to the US. It was one of the major points he drove home to the pharmaceutical industry in a meeting that was held recently – the issue of job creation. He demanded that the industry bring a number of manufacturing jobs back to the US and also to increase investment in manufacturing sites.

Advertisement

It was a line that was met warmly by the CEOs, when improvements to the speed at which drugs can reach the market was offered in return. It is being speculated that this may be the reason behind Eli Lilly’s decision to review its investment in the Cork site. If Trump plays hardball with the manufacturing line then the delay could be to potentially divert funds to US sites.

Eli Lilly has not yet released the reason for the delay but commented that the decision will be made available at the “appropriate stage”.

Ben Hargreaves

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content